Nanomedicine News

RSS

Matinas BioPharma to Provide Update on MAT2203 Phase 2a Clinical Study at 14th Annual BIO Investor Forum

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14th Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.

15 Oct 2015

Nanomedical Diagnostics Completes $1.6 Million Series A Financing Round

Nanomedical Diagnostics, a biotech company developing and commercializing bioelectronics for use in research and diagnostics, announces the completion of a Series A financing round of $1.6 million led by Serra Ventures.

15 Oct 2015

Laser-Based Stimulated Raman Scattering Microscopy Could Help Differentiate Between Tumor Tissue and Normal Brain

Brain tumor tissue can be hard to distinguish from normal brain during surgery. Neurosurgeons use their best judgment in the operating room but often must guess exactly where the edges of the tumor are while removing it.

15 Oct 2015

New Tool to Identify Unstable or High Risk Atherosclerotic Plaques

Researchers have developed and validated a new tool to help identify unstable or high risk atherosclerotic plaques--inflamed fatty deposits in the artery wall and a main contributor to cardiovascular disease (CVD). This breakthrough may lead to better identifying which plaques are considered at the highest risk for rupturing and causing a heart attack or stroke.

14 Oct 2015

Providence Introduces Nano-Textured Surface Technology to DTRAX Line of Tissue-Sparing Devices to Enhance Cervical Fusion Process

Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today introduced its proprietary Cavux™ surface technology, designed to speed bone fusion during the healing process. The company’s portfolio of DTRAX® Cervical Cage implants will be available with Cavux, a unique surface technology that produces micro-textures on titanium surfaces. The micro- and nano-textures created across the implant surface area serve to enhance the fusion process.

14 Oct 2015

Computational Modeling Enables Design of Sturdier Liposome

Using computational modeling, researchers at Carnegie Mellon University, the Colorado School of Mines and the University of California, Davis have come up with a design for a better liposome. Their findings, while theoretical, could provide the basis for efficiently constructing new vehicles for nanodrug delivery.

14 Oct 2015

ETPN to Help EU Companies Bring Innovative Nanomedicines to Market

Patrick Boisseau, chairman of the European Technology Platform on Nanomedicine (ETPN), said today that nanomedicine in Europe is rapidly progressing from a primarily academic-research-oriented and fragmented field to a multi-national program sharply focused on bringing the benefits of nanomedicine to all Europeans.

From CEA-Leti 14 Oct 2015

NCI Awards Five-Year, $1.8 Million Training Grant for Nanotechnology to Treat Cancer

Rice University and the University of Texas MD Anderson Cancer Center have won a five-year, $1.8 million grant from the National Cancer Institute (NCI) to train graduate students and postdoctoral research associates to translate nanotechnology breakthroughs into clinical treatments for cancer patients.

13 Oct 2015

Titan Spine’s FDA-Cleared nanoLOCK Surface Technology Wins Orthopedics This Week’s 2015 Spine Technology Awards

Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has been recognized as a winner of Orthopedics This Week’s 2015 Spine Technology Awards in the Biomaterials and Biologics category. Furthermore, Titan Spine’s nanoLOCK™ surface technology, the only FDA-cleared nanotechnology for the spine, scored highest of all products submitted.

13 Oct 2015

Matinas’ Cochleate Lipid-Crystal Nano-Particle Technology Improves Efficacy of Atovaquone in Treating Pneumocystis Pneumonia

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, announces the presentation of pre-clinical data that shows its cochleate lipid-crystal nano-particle drug delivery technology significantly improves the efficacy of atovaquone in treating pneumocystis pneumonia (PCP), and enhances lung tissue penetration.

12 Oct 2015